Form 4: Bolt Biotherapeutics Director Acquires 22,000 Stock Options

Laura Berner, a director of Bolt Biotherapeutics, acquired 22,000 stock options on June 12, 2024, at an exercise price of $0.7682.

Summary

• Laura Berner, a director at Bolt Biotherapeutics, acquired 22,000 stock options on June 12, 2024.
• The exercise price for these options is $0.7682.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• The options will fully vest upon a change in control of Bolt Biotherapeutics.
• The options expire on June 11, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While it can be seen as a positive sign of confidence, it's not a major event.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule and change in control provision suggest a focus on long-term value creation and potential strategic events.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This is a standard practice in the biopharmaceutical industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biopharmaceutical industry to align their interests with those of shareholders.
• The vesting schedule is typical, often tied to continued service and corporate milestones.
• Companies like Amgen, Gilead, and Regeneron also use stock options as part of their director compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director can align their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates